Drug Patents owned by Cumberland Pharms

1. Drug name - ACETADOTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof Aug, 2025

(2 years from now)

US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof Aug, 2025

(2 years from now)

US8148356 CUMBERLAND PHARMS Acetylcysteine composition and uses therefor May, 2026

(3 years from now)

US9327028 CUMBERLAND PHARMS Acetylcysteine compositions and methods of use thereof Jul, 2031

(8 years from now)

US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof Apr, 2032

(9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6GM/30ML (200MG/ML) INJECTABLE;INTRAVENOUS Prescription

2. Drug name - CALDOLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138404 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US9114068 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US8735452 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US9649284 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US8871810 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US9295639 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen Sep, 2029

(6 years from now)

US9012508 CUMBERLAND PHARMS Administration of intravenous ibuprofen Sep, 2030

(7 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation Mar, 2032

(9 years from now)

US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation Mar, 2032

(9 years from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
400MG/4ML (100MG/ML) SOLUTION;INTRAVENOUS Discontinued
800MG/8ML (100MG/ML) SOLUTION;INTRAVENOUS Prescription
800MG/200ML (4MG/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - VIBATIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6635618 CUMBERLAND PHARMS Glycopeptide phosphonate derivatives
Sep, 2023

(11 months from now)

US7531623 CUMBERLAND PHARMS Hydrochloride salts of a glycopeptide phosphonate derivative
Jan, 2027

(4 years from now)

CN100532392C CUMBERLAND PHARMS Reductive Alkylation Method
May, 2021

(1 year, 5 months ago)

CN100469788C CUMBERLAND PHARMS Glycopeptide Phosphonic Acid Salt Derivatives
May, 2021

(1 year, 5 months ago)

CN1432023A CUMBERLAND PHARMS Reductive Alkylation Process
May, 2021

(1 year, 5 months ago)

CN1437611A CUMBERLAND PHARMS Glycopeptide Phosphonic Acid Salt Derivatives
May, 2021

(1 year, 5 months ago)

CN1223378C CUMBERLAND PHARMS Pharmaceutical Compositions Containing A Glycopeptide Antibiotic And A Cyclodextrin
May, 2021

(1 year, 5 months ago)

CN1441680A CUMBERLAND PHARMS Pharmaceutical Compositions Containing A Glycopeptide Antibiotic And A Cyclodextrin
May, 2021

(1 year, 5 months ago)

CN1871253A CUMBERLAND PHARMS Hydrochloride Of Glycopeptide Phosphonate Derivatives
Oct, 2024

(2 years from now)

CN100417661C CUMBERLAND PHARMS Hydrochloride Of Glycopeptide Phosphonate Derivatives
Oct, 2024

(2 years from now)

IN200201986P4 CUMBERLAND PHARMS Glycopeptide Phosphonate Derivatives
May, 2021

(1 year, 5 months ago)

IN206947B CUMBERLAND PHARMS Glycopeptide Phosphonate Derivatives
May, 2021

(1 year, 5 months ago)

EP1276759B1 CUMBERLAND PHARMS Reductive Alkylation Process On Glycopeptides
Apr, 2021

(1 year, 5 months ago)

EP1278549B1 CUMBERLAND PHARMS Composition Containing A Cyclodextrin And A Glycopeptide Antibiotic
Apr, 2021

(1 year, 5 months ago)

EP1276759A2 CUMBERLAND PHARMS Reductive Alkylation Process On Glycopeptides
Apr, 2021

(1 year, 5 months ago)

EP1278549A2 CUMBERLAND PHARMS Composition Containing A Cyclodextrin And A Glycopeptide Antibiotic
Apr, 2021

(1 year, 5 months ago)

EP1292611A2 CUMBERLAND PHARMS Glycopeptide Carboxy-Saccharide Derivatives
May, 2021

(1 year, 5 months ago)

EP1292611B1 CUMBERLAND PHARMS Glycopeptide Carboxy-Saccharide Derivatives
May, 2021

(1 year, 5 months ago)

EP1678201A2 CUMBERLAND PHARMS Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative
Oct, 2024

(2 years from now)

EP1678201B1 CUMBERLAND PHARMS Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative
Oct, 2024

(2 years from now)

EP2495251B1 CUMBERLAND PHARMS Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative
Oct, 2024

(2 years from now)

EP2495251A1 CUMBERLAND PHARMS Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative
Oct, 2024

(2 years from now)

EP1292612B1 CUMBERLAND PHARMS Glycopeptide Phosphonate Derivatives
May, 2026

(3 years from now)

EP1292612A2 CUMBERLAND PHARMS Glycopeptide Phosphonate Derivatives
May, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE/VIAL POWDER;INTRAVENOUS Discontinued
EQ 750MG BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.